+357 96 030922
info@marketpublishers.com

Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug (Naltrexone, Buprenorphine, Methadone), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

https://marketpublishers.com/r/O0998326DB5DEN.html
Date: December 2024
Pages: 150
Price: US$ 5,950.00 (Single User License)
ID: O0998326DB5DEN

Abstracts

This report can be delivered to the clients within 3 Business Days

Opioid Use Disorder Market Growth & Trends

The global opioid use disorder market size is expected treach USD 10.24 billion by 2030, according ta new report by Grand View Research, Inc., exhibiting a CAGR of 11.15% from 2025 t2030. Rising opioid epidemic and growing government initiatives tcombat the crisis are likely tpropel market growth. In addition, growing commercialization of novel products is further anticipated tdrive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according tthe National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted tprescribed drugs.

According tthe CDC, around 130 Americans die every day due tthe opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting tovercome their addiction, adherence ta Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

+357 96 030922
info@marketpublishers.com

Tcombat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 timprove standard of care. Furthermore, in 2016, the U.S. FDA announced plans toverhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

Opioid Use Disorder Market Report Highlights

Buprenorphine led the market and accounted for 59.58% of the global revenue in 2024 due tits effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk.

The injectable segment dominated the market and accounted for 59.26% of the global revenue in 2024. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse.

Hospital pharmacies dominated the market with a market share of 47.90% in 2024 due ttheir integral role in managing complex and severe cases.

North America opioid use disorder market accounted for 68.98% share in 2024 due tseveral key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions.

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

1.1. Market Segmentation & Scope
1.2. Segment Definitions
  1.2.1. Drug
  1.2.2. Route of Administration
  1.2.3. Distribution Channel
  1.2.4. Regional scope
  1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
  1.4.1. Purchased database
  1.4.2. GVR's internal database
  1.4.3. Secondary Distribution Channels
  1.4.4. Primary research
  1.4.5. Details of primary research
    1.4.5.1. Data for primary interviews in North America
    1.4.5.2. Data for primary interviews in Europe
    1.4.5.3. Data for primary interviews in Asia Pacific
    1.4.5.4. Data for primary interviews in Latin America
    1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
  1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
  1.7.1. Commodity flow analysis (Model 1)
  1.7.2. Approach 1: Commodity flow approach
  1.7.3. Volume price analysis (Model 2)
  1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Distribution Channels
1.9. List of Primary Distribution Channels
1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Outlook
2.2. Segment Outlook

+357 96 030922
info@marketpublishers.com

2.2.1. Drug
2.2.2. Route of Administration
2.2.3. Distribution Channel
2.2.4. Regional outlook
2.3. Competitive Insights

CHAPTER 3. OPIOID USE DISORDER MARKET VARIABLES, TRENDS & SCOPE

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising opioid epidemic
3.2.1.2. Growing government initiatives to combat the crisis
3.2.1.3. Growing awareness of opioid use disorder (OUD)
3.2.2. Market restraint analysis
3.2.2.1. Adverse effects associated to drug used for opioid treatment
3.2.2.2. Complex reimbursement structure
3.3. Opioid Use Disorder Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Pricing Analysis
3.5. Pipeline Analysis
3.6. Qualitative analysis about Behavioral Therapies

CHAPTER 4. OPIOID USE DISORDER MARKET ANALYSIS, BY DRUG, 2018-2030 (USD MILLION)

4.1. Drug Market Share, 2024 & 2030
4.2. Segment Dashboard

+357 96 030922
info@marketpublishers.com

4.3. Global Opioid Use Disorder Market by Drug Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Buprenorphine
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Belbuca
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Suboxone
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Zubsolv
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Others
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Methadone
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Naltrexone
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. OPIOID USE DISORDER MARKET ANALYSIS, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)

5.1. Opioid Use Disorder: Route of Administration Movement Analysis
5.2. Opioid Use Disorder Market Analysis, by Route of Administration Market (USD Million)
5.2.1. Oral Administration
5.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.2.2. Injectable Administration
5.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.2.3. Others
5.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

CHAPTER 6. OPIOID USE DISORDER MARKET ANALYSIS, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)

6.1. Opioid Use Disorder: Distribution Channel Movement Analysis
6.2. Opioid Use Disorder Market Analysis, by Distribution Channel Market (USD Million)
6.2.1. Hospital Pharmacies
6.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

+357 96 030922
info@marketpublishers.com

6.2.2. Retail Pharmacies
6.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
6.2.3. Others
6.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

CHAPTER 7. OPIOID USE DISORDER MARKET: REGIONAL ESTIMATES AND TREND ANALYSIS BY DRUG, BY ROUTE OF ADMINISTRATION, BY DISTRIBUTION CHANNEL

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario

+357 96 030922
info@marketpublishers.com

7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics

+357 96 030922
info@marketpublishers.com

7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Argentina
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario

+357 96 030922
info@marketpublishers.com

7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Indivior PLC
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Drug benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Teva Pharmaceutical Industries, Ltd.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Drug benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Pfizer, Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Drug benchmarking

+357 96 030922
info@marketpublishers.com

8.3.6.4. Strategic initiatives
8.3.7. BioDelivery Sciences International, Inc. (a part of Collegium Pharmaceutical, Inc.)
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Drug benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Genentech, Inc. (Roche)
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Drug benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Alkermes.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Drug benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Orexo US Inc. (subsidiary of Orexo AB)
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Drug benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Titan Pharmaceuticals, Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Drug benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Omeros Corporation
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Drug benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Camurus AB
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Drug benchmarking
8.3.13.4. Strategic initiatives
8.3.14. Hikma Pharmaceuticals PLC
8.3.14.1. Company overview

+357 96 030922
info@marketpublishers.com

8.3.14.2. Financial performance
8.3.14.3. Drug benchmarking
8.3.14.4. Strategic initiatives

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Opioid Use Disorder Market Size, Share & Trends Analysis Report By Drug (Naltrexone, Buprenorphine, Methadone), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Product link: https://marketpublishers.com/r/O0998326DB5DEN.html

Price: US$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/O0998326DB5DEN.html